BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$2.63 USD
+0.02 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.61 -0.02 (-0.76%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for BioXcel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 0 | 0 | 0 |
Cost Of Goods | 1 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 172 | 160 | 107 | 82 | 34 |
Income After Depreciation & Amortization | -172 | -160 | -107 | -82 | -34 |
Non-Operating Income | 6 | 2 | 0 | 0 | 1 |
Interest Expense | 13 | 8 | 0 | 0 | 0 |
Pretax Income | -179 | -166 | -107 | -82 | -33 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -179 | -166 | -107 | -82 | -33 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -179 | -166 | -107 | -82 | -33 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -171 | -159 | -107 | -82 | -33 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -172 | -160 | -107 | -82 | -34 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.13 | 28.02 | 26.37 | 21.68 | 16.29 |
Diluted EPS Before Non-Recurring Items | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 |
Diluted Net EPS (GAAP) | -6.15 | -5.92 | -4.05 | -3.79 | -2.02 |
Fiscal Year end for BioXcel Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.38 | 0.34 | 0.46 | 0.21 |
Cost Of Goods | NA | 0.71 | 0.51 | 0.03 | 0.01 |
Gross Profit | NA | -0.34 | -0.17 | 0.43 | 0.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.53 | 48.13 | 52.84 | 51.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -19.87 | -48.30 | -52.41 | -51.20 |
Non-Operating Income | NA | 1.05 | 1.06 | 2.16 | 1.77 |
Interest Expense | NA | 3.44 | 3.25 | 3.26 | 3.37 |
Pretax Income | NA | -22.26 | -50.49 | -53.52 | -52.80 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -22.26 | -50.49 | -53.52 | -52.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -22.26 | -50.49 | -53.52 | -52.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.45 | 29.27 | 29.19 | 28.62 |
Diluted EPS Before Non-Recurring Items | NA | -0.76 | -1.72 | -1.83 | -1.84 |
Diluted Net EPS (GAAP) | NA | -0.76 | -1.72 | -1.83 | -1.84 |